The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Statistical Approaches to Evaluate Analytical Similarity.'' This draft guidance, when finalized, will provide advice on the evaluation of analytical similarity to sponsors interested in developing biosimilar products. Specifically, this draft guidance describes the type of information a sponsor of a proposed biosimilar product should obtain about the structural/physicochemical and functional attributes of the reference product, how that information is used in the development of an analytical similarity assessment plan for the proposed biosimilar, and the statistical approaches recommended for evaluating analytical similarity.
Document
Statistical Approaches To Evaluate Analytical Similarity; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Statistical Approaches to Evaluate Analytical Similar...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 44425
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Statistical Approaches To Evaluate Analytical Similarity; Draft Guidance for Industry; Availability,” thefederalregister.org (September 22, 2017), https://thefederalregister.org/documents/2017-20263/statistical-approaches-to-evaluate-analytical-similarity-draft-guidance-for-industry-availability.